Fig. 1From: FOXO3a-dependent PARKIN negatively regulates cardiac hypertrophy by restoring mitophagyPARKIN negatively regulated cardiac hypertrophy in mice. A, Immunoblotting results showing the protein levels of PARKIN in mice hearts infused with angiotensin (Ang II) or not. n = 3 experiments per group. B, Immunoblotting results showing the protein levels of PARKIN in hearts of Parkin transgenic mice or wide-type (WT) mice. n = 3 experiments per group. C − E, Parkin transgenic mice exhibited reduced hypertrophic responses and cardiac fibrosis. Parkin transgenic mice and WT mice were infused with Ang II. C Top row: gross hearts (bar = 1.5 mm); bottom row: heart sections stained with hematoxylin and eosin (bar = 20 µm); right: the ratio of heart weight to body weight. * p < 0.05. ** p < 0.01. n = 5 experiments per group. D The mRNA levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) detected by qRT-PCR. The results were normalized to GAPDH. *** p < 0.001. ****p < 0.0001. n = 6 experiments per group. (E) Heart sections stained with Masson trichrome (left) and the fibrotic area analysis (right) (bar = 50 µm); ** p < 0.01. *** p < 0.001. n = 5 experiments per group. F and G, Parkin transgenic mice exhibited reduced cardiac remodeling and improved cardiac function in response to Ang II. F TRITC-conjugated wheat germ agglutinin staining was used to assessed cross-sectional area of hearts from WT mice and Parkin transgenic mice with Ang II infusions (left). The cross-sectional area was calculated (right). Bar = 100 µm; ** p < 0.01. *** p < 0.001. n = 6 experiments per group. G End-systolic interventricular septum thickness (IVSs) was measured. * p < 0.05. ** p < 0.01. n = 6 experiments per groupBack to article page